Biliary sludge: pathogenesis, etiology and drug therapy
- Authors: Bakulin I.G.1, Avalueva E.B.1, Serkova M.U.1, Skvortsova T.E.1, Seliverstov P.V.1, Shevyakov M.A.1, Sitkin S.I.1,2
-
Affiliations:
- Mechnikov North-Western State Medical University
- Almazov National Medical Research Centre
- Issue: Vol 93, No 2 (2021)
- Pages: 179-186
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/64749
- DOI: https://doi.org/10.26442/00403660.2021.02.200638
- ID: 64749
Cite item
Full Text
Abstract
Aim. To evaluate the effectiveness of the use of ursodeoxycholic acid (UDCA) for the treatment of biliary sludge (BS) and to compare the therapeutic effectiveness of the German substance UDCA and generic drugs from other manufacturers.
Materials and methods. The study involved 65 patients diagnosed with BS (K80.8). To assess the severity of BS, ultrasound of the gallbladder was performed before treatment, after 1, 3, 6 months during therapy, as well as an assessment of its contractility. All patients were randomized into 2 groups. Patients of the main group received UDCA Ursofalk (Germany) at a dose of 10 mg/kg for at least 6 months. Patients in the comparison group received UDCA (another manufacturer) at a dose of 10 mg/kg for at least 6 months.
Results. After 3 months of follow-up, the number of patients with dissolved sludge in the main group was 87.1%, while in the comparison group – 50%. In 71% of patients, the normalization of the lean volume of the gallbladder was noted, and in the comparison group only in 47.1%. After 6 months of follow-up, complete resolution of BS in the main group was observed in 93.5% of cases, and in the comparison group in 73.6% of cases.
Conclusion. As a result of the study, the high effectiveness of Ursofalk during oral litolysis in patients with stage I GI (BS) in the first 3 months of therapy, as well as the normalization of the contractile function of the gallbladder, were noted.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
I. G. Bakulin
Mechnikov North-Western State Medical University
Email: avalueva@mail.ru
ORCID iD: 0000-0002-6151-2021
д.м.н., проф., зав. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса ФГБОУ ВО «СЗГМУ им. И.И. Мечникова»
Russian Federation, Saint PetersburgE. B. Avalueva
Mechnikov North-Western State Medical University
Author for correspondence.
Email: avalueva@mail.ru
ORCID iD: 0000-0001-6011-0998
д.м.н., проф. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса ФГБОУ ВО «СЗГМУ им. И.И. Мечникова»
Russian Federation, Saint PetersburgM. U. Serkova
Mechnikov North-Western State Medical University
Email: avalueva@mail.ru
ORCID iD: 0000-0001-9600-3131
к.м.н., ассистент каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса ФГБОУ ВО «СЗГМУ им. И.И. Мечникова»
Russian Federation, Saint PetersburgT. E. Skvortsova
Mechnikov North-Western State Medical University
Email: avalueva@mail.ru
ORCID iD: 0000-0002-9362-9961
к.м.н., доц. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса ФГБОУ ВО «СЗГМУ им. И.И. Мечникова»
Russian Federation, Saint PetersburgP. V. Seliverstov
Mechnikov North-Western State Medical University
Email: avalueva@mail.ru
к.м.н., доц. каф. внутренних болезней, клинической фармакологии и нефрологии ФГБОУ ВО «СЗГМУ им. И.И. Мечникова»
Russian Federation, Saint PetersburgM. A. Shevyakov
Mechnikov North-Western State Medical University
Email: avalueva@mail.ru
ORCID iD: 0000-0002-1440-3017
д.м.н., проф. каф. клинической микологии, иммунологии и аллергологии ФГБОУ ВО «СЗГМУ им. И.И. Мечникова»
Russian Federation, Saint PetersburgS. I. Sitkin
Mechnikov North-Western State Medical University; Almazov National Medical Research Centre
Email: avalueva@mail.ru
ORCID iD: 0000-0003-0331-0963
к.м.н., доц. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса ФГБОУ ВО «СЗГМУ им. И.И. Мечникова», зав. НИГ эпигенетики и метагеномики Института перинатологии и педиатрии ФГБУ «НМИЦ им. В.А. Алмазова»
Russian Federation, Saint Petersburg; Saint PetersburgReferences
- Вялов С.С. Различия в эффективности лечения желчнокаменной болезни и билиарного сладжа разными препаратами урсодезоксихолевой кислоты. Consilium Medicum. 2017;19(8.2):64-8 [Vyalov SS. Differences in the effectiveness of treatment of cholelithiasis and biliary sludge with various drugs of ursodeoxycholic acid. Consilium Medicum. 2017;19(8.2):64-8 (In Russ.)].
- Ильченко А.А. 10 лет классификации желчнокаменной болезни (ЦНИИГ): основные итоги научно-практического применения. Экспериментальная и клиническая гастроэнтерология. 2012;4:3-6 [Il’chenko AA. 10 let klassifikacii zhelchnokamennoj bolezni (CNIIG): osnovnye itogi nauchno-prakticheskogo primeneniya. Eksperimental’naya i klinicheskaya gastroenterologiya. 2012;4:3-6 (In Russ.)].
- European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016;65(1):146-81. doi: 10.1016/j.jhep.2016.03.005
- Царькова О.Н., Запруднов А.М., Харитонова Л.А. и др. Билиарный сладж: клинико-диагностические и лечебно-профилактические аспекты. Рос. вестн. перинатологии и педиатрии. 2009;54(6):38-42 [Car’kova ON, Zaprudnov AM, Haritonova LA, et al. Biliarnyj sladzh: kliniko-diagnosticheskie i lechebno-profilakticheskie aspekty. Ros. vestn. perinatologii i pediatrii. 2009;54(6):38-42 (In Russ.)].
- Sporea L. О частоте выявления «желчного сладжа» с помощью УЗИ. Мед. журн. Sono Ace International. 1999;5;34-9 [Sporea L. O chastote vyyavleniya «zhelchnogo sladzha» s pomoshch’yu UZI. Med. zhurn. Sono Ace International. 1999;5:34-9 (In Russ.)].
- Полунина Т.Е. Билиарный сладж. Алгоритмы диагностики, схемы терапии. Трудный пациент. 2013;11(10):42-6 [Polunina TE. Biliarnyj sladzh. Algoritmy diagnostiki, skhemy terapii. Trudnyj pacient. 2013;11(10):42-6 (In Russ.)].
- Минушкин О.Н., Бурдина Е.Г., Новоженова Е.В. Билиарный сладж. Эпидемиология, факторы риска, формирование, диагностика, лечебные подходы. Мед. алфавит. 2017;2(19):5-8 [Minushkin ON, Burdina EG, Novozhenova EV. Biliarnyj sladzh. Epidemiologiya, faktory riska, formirovanie, diagnostika, lechebnye podhody. Med. alfavit. 2017;2(19):5-8 (In Russ.)].
- Gutt C, Jenssen C, Barreiros AP, et al. Aktualisierte S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs – und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein – und Viszeralchirurgie (DGAV) zur Prävention, Diagnostik und Behandlung von Gallensteinen. Z Gastroenterol. 2018;56:912-66. doi: 10.1055/a-0643-4420
- Lammert F, Hirschfield G, Adams D, Liaskou E. Gallstone Disease: Scientific Understanding and Future Treatment. Biliary Disease. Springer, Cham. 2017; p. 229-41. doi: 10.1007/978-3-319-50168-0_11
- Holzbach RT, Marsh M, Olszewski M, Holan K. Cholesterol solubility in bile. Evidence that supersaturated bile is frequent in healthy man. J Clin Invest. 1973;52:1467-79. doi: 10.1172/JCI107321
- Jirsa M, Groen AK. Role of biliary proteins and non-protein factors in kinetics of cholesterol crystallisation and gallstone growth. Front Biosci. 2001;6:154-67. doi: 10.2741/jirsa
- Portincasa P, Di Ciaula A, Baldassarre G, et al. Gallbladder motor function in gallstone patients: sonographic and in vitro studies on the role of gallstones, smooth muscle function and gallbladder wall inflammation. J Hepatol. 1994;21:430-40. doi: 10.1016/s0168-8278(05)80324-1
- Kriegermeier A, Green R. Pediatric Cholestatic Liver Disease: Review of Bile Acid Metabolism and Discussion of Current and Emerging Therapies. Front Med (Lausanne). 2020;7:149. doi: 10.3389/fmed.2020.00149
- Гирса В.Н., Немцов Л.М. Билиарный сладж: клиническое значение и диагностика. Вестн. Витебского гос. мед. ун-та. 2013;12(4):19-26 [Girsa VN, Nemcov LM. Biliarnyj sladzh: klinicheskoe znachenie i diagnostika. Vestn. Vitebskogo gos. med. un-ta. 2013;12(4):19-26 (In Russ.)].
- Wang J-Y, Wu S-D, Abenavoli L, et al. Ursodeoxycholic Acid for the Treatment of Liver Diseases. Liver Pathophysiol Ther Antioxidants. 2017; p. 767-79. doi: 10.1016/B978-0-12-804274-8.00055
- Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol. 1994;204:1-15. doi: 10.3109/00365529409103618
- Агафонова Н.А., Яковенко Э.П., Яковенко А.В., Иванов А.Н. Билиарный сладж: возможности консервативной терапии. Лечебное дело. 2016;3:14-20 [Agafonova NA, Yakovenko EP, Yakovenko AV, Ivanov AN. Biliarnyj sladzh: vozmozhnosti konservativnoj terapii. Lechebnoe delo. 2016;3:14-20 (In Russ.)].
- Радченко В.Г., Селиверстов П.В., Ситкин С.И. Новые аспекты фармакологического действия урсодеоксихолевой кислоты. Экспериментальная и клин. гастроэнтерология. 2014;8: 4-10 [Radchenko VG, Seliverstov PV, Sitkin SI. New aspects of pharmacological effects of ursodeoxycholic acid. Eksp Klin Gastroenterol. 2014;8:4-10 (In Russ.)]. doi: 10.1016/s0002-9343(00)00318-1
- Ивашкин В.Т., Маев И.В., Шульпекова Ю.О. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению дискинезии желчевыводящих путей. Рос. журн. астроэнтерологии, гепатологии, колопроктологии. 2018;28(3):63-80 [Ivashkin VT, Maev IV, SHul’pekova YuO, et al. Klinicheskie rekomendacii Rossijskoj gastroenterologicheskoj associacii po diagnostike i lecheniyu diskineziizhelchevyvodyashchih putej. Ros. zhurn. astroenterologii, gepatologii, koloproktologii. 2018;28(3):63-80 (In Russ.)]. doi: 10.22416/1382-4376-2018-28-1-55-70
- Ozel Coskun BD, Yucesoy M, Gursoy S, et al. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apoli-poprotein B/A1 ratio in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2015;27(2):142-9. doi: 10.1097/MEG.0000000000000264
- Roma MG, Toledo FD, Boaglio AC, et al. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond). 2011;121:523-44. doi: 10.1042/CS20110184
- Кравченко Е.В. Новый белорусский препарат урсодезоксихолевой кислоты «Урсаклин»: возможности и перспективы применения. Мед. новости. 2013;12:18-22 [Kravchenko EV. Novyj belorusskij preparat ursodezoksiholevoj kisloty «Ursaklin»: vozmozhnosti i perspektivy primeneniya Med. novosti. 2013;12:18-22 (In Russ.)].
- Агафонова Н.А. Билиарный сладж тактика ведения и лечения. Мед. совет. 2012;9:28-33 [Agafonova NA. Biliarnyj sladzh taktika vedeniya i lecheniya. Med. sovet. 2012;9:28-33 (In Russ.)].
- Селиверстов П.В., Скворцова Т.Э., Ситкин С.И., Радченко В.Г. Возможности терапевтического лечения больных желчнокаменной болезнью. Мед. совет. 2019;14:44-51 [Seliverstov PV, Skvortsova TE, Sitkin SI, Radchenko VG. Treatment Options for Patients with Gallstones (Cholelithiasis). Meditsinskiy sovet = Medical Council. 2019;14:44-51 (In Russ.)]. doi: 10.21518/2079-701X-2019-14-44-51
- Сарвилина И.В. Сравнительный клинико-экономический анализ применения препаратов урсодезоксихолевой кислоты у пациентов с желчнокаменной болезнью 1 стадии. Лечащий врач. 2015;2:64-8 [Sarvilina IV. Sravnitel’nyj kliniko-ekonomicheskij analiz primeneniya preparatov ursodezoksiholevoj kisloty u pacientov s zhelchnokamennoj bolezn’yu 1 stadii. Lechashchij vrach. 2015;2:64-8 (In Russ.)].
- Мехтиев С.Н., Гриневич В.Б., Кравчук Ю.А., Богданов Р.Н. Билиарный сладж: нерешенные вопросы. Лечащий врач. 2007;6:24-8 [Mekhtiev SN, Grinevich VB, Kravchuk YuA, Bogdanov RN. Biliarnyj sladzh: nereshennye voprosy. Lechashchij Vrach. 2007;6:24-8 (In Russ.)]. doi: 10.21518/2079-701X-2018-14-90-96
- Sugerman H, Brewer W, Shiffman M, et al. A multicenter, placebo-controlled, randomized, double blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypassinduced rapid weight loss. Am J Surg. 1995;169(1):91-6. doi: 10.1016/s0002-9610(99)80115-9
- Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol. 2006;20:981-96. doi: 10.1016/j.bpg.2006.05.004
- Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology. 1999;117:632-9. doi: 10.1016/s0016-5085(99)70456-7
- Lee YJ, Park YS, Park JH. Cholecystectomy is Feasible in Children with Small-Sized or Large Numbers of Gallstones and in Those with Persistent Symptoms Despite Medical Treatment. Pediatr Gastroenterol Hepatol Nutr. 2020;23(5):430-8. doi: 10.5223/pghn.2020.23.5.430
- Tsai TJ, Chan HH, Lai KH, et al. Gallbladder function predicts subsequent biliary complications in patients with common bile duct stones after endoscopic treatment? BMC Gastroenterol. 2018;18(1):32. doi: 10.1186/s12876-018-0762-6
- Russo MW, Wei JT, Thiny MT, et al. Digestive and liver diseases statistics, 2004. Gastroenterology. 2004;126:1448-53. doi: 10.1053/j.gastro.2004.01.025
- Latenstein CSS, de Jong JJ, Eppink JJ, Lantinga MA, et al. Prevalence of dyspepsia in patients with cholecystolithiasis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019 Aug;31(8):928-34. doi: 10.1097/MEG.0000000000001463
- Lamberts MP. Indications of cholecystectomy in gallstone disease. Curr Opinion Gastroenterol. 2018;34 (2):97-102. doi: 10.1097/MOG.0000000000000419